Results 281 to 290 of about 545,624 (314)
Some of the next articles are maybe not open access.
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
The Lancet Oncology, 2017 Yi-long Wu, Ying Cheng, Xiang-dong Zhou, K. Lee, K. Nakagawa, S. Niho, F. Tsuji, R. Linke, R. Rosell, J. Corral, M. Migliorino, A. Płużański, E. Sbar, Tao Wang, Jane Liang White, S. Nadanaciva, R. Sandin, T. Mok +17 moresemanticscholar +1 more sourceAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
The Lancet Oncology, 2014 Yi-long Wu, Caicun Zhou, Cheng-ping Hu, Jifeng Feng, Shun Lu, Yunchao Huang, Wei Li, M. Hou, Jianhua Shi, K. Lee, Chongrui Xu, D. Massey, Miyoung Kim, Yang Shi, Sarayut Lucien Geater +14 moresemanticscholar +1 more source
